Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269394 · ClinicalTrials.gov registry record · Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
A Phase 2 study of Dementia and Alzheimers Disease, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
- 20
- Study locations
NCT05269394 is a Phase 2 study of Dementia and Alzheimers Disease that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 197 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT05269394, a Phase 2 study of Dementia and Alzheimers Disease, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
Conditions Studied
Interventions
- DRUG Lecanemab
- DRUG E2814
- DRUG Matching Placebo (E2814)
Study Locations (20)
Other
- Instituto de Investigaciones Neurologicas Raul Carrea, FLENI - Ciudad Autonoma de Buenos Aire
- Hospital das Clínicas da Faculdade de Medicina da USP - São Paulo
- CHU de Quebec - Hôpital de l' Enfant Jésus - Québec
- Grupo de Neurociencias Sede de la Universidad de Antioquia - Medellín
California
- University of California San Diego Medical Center - La Jolla
- USC Keck School of Medicine - Los Angeles
Alabama
- University of Alabama in Birmingham - Birmingham
Connecticut
- Yale University School of Medicine - New Haven
Georgia
- Emory University - Atlanta
Illinois
- Advocate Lutheran General Hospital - Park Ridge
Indiana
- Indiana University School of Medicine - Indianapolis
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269394
The ClinicalTrials.gov registry entry for NCT05269394 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (97% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dementia appearing as the primary indexed condition, and to 3 interventions - of which Lecanemab is the first listed.
NCT05269394 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05269394 about?
NCT05269394 is a clinical study titled "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)". To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive ...
What is the current status of trial NCT05269394?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2021-12-22. Estimated completion is 2028-07.
What conditions does trial NCT05269394 study?
This clinical trial studies the following conditions: Dementia, Alzheimers Disease, Alzheimers Disease, Familial.
What interventions are being tested in trial NCT05269394?
The interventions under investigation include: Lecanemab (DRUG), E2814 (DRUG), Matching Placebo (E2814) (DRUG).
Who is sponsoring clinical trial NCT05269394?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05269394 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Testing the Pain Clinical Practice Guideline
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.